In the meantime, the most commonly used assessment tool in the area is the Inventory of Complicated Grief (ICG). It was developed by Prigerson and colleagues11 and focuses on symptoms that are distinguishable

from symptoms of depression and anxiety (eg, reactions such as preoccupation with thoughts of the deceased, disbelief about the death and nonacceptance of its reality). Moreover, the ICG was designed Inhibitors,research,lifescience,medical to distinguish between normal reactions and more pathological forms. The ICG consists of 19 Items (eg, “ever since she died it is hard for me to trust people”). Its convergent and discriminant validity yielded excellent results. High ICG values were associated with a lower quality of life. Moreover, scores at 6 months after loss predicted risk of cancer, high blood pressure, heart trouble, smoking, and eating problems 1 to 2 years later.23 In an attempt to compare the ICG with Horowitz’s concept of PGD, Forstmeier and Maercker24 Inhibitors,research,lifescience,medical conducted a comparative study using a 30-item questionnaire

according Inhibitors,research,lifescience,medical to the Horowitz model.9 They found only a small convergent validity between the two assessments. The ChemSelleck IKK inhibitor authors concluded that the main reasons for this nonconvergence were the number of symptoms or criteria that had to be present In order to diagnose PGD. For the most recent consensus criteria on PGD (see above13), no validated clinical assessment has so far been published. However, a short screening scale, the PG-13, Inhibitors,research,lifescience,medical has been developed by Prigerson’s group14 and it has already been used in several studies (eg, ref 25). It is a promising tool to investigate PGD in various populations and has the advantage of being short and comprehensive. Epidemiology Inhibitors,research,lifescience,medical To date, there are no methodologically

sound studies that provide information about the prevalence of complicated grief in the general population. However, two issues are of particular interest. First, the general prevalence (eg, 1-year prevalence). The second is the conditional probability: the proportion of bereaved persons who develop PGD. Various authors have reported probabilities of around 10%, 13,26 implying that almost one third of all bereaved develop PGD. So far, Electron transport chain the only representative epidemiological studies are on elderly samples, Including persons 60 to 94 years old.27,28 In the Swiss population within this age group, 4.2% of the 712 participants were diagnosed with PGD based on the previous Horowitz criteria.28 Women were diagnosed more often: 5.8% of all women, against 2.1% of men. The conditional probability was 16%, meaning that one out of six had the disorder. Patients with PGD had 1.9 (SD 1.0) comorbid psychiatric disorders with subthreshold depression as the most frequent comorbid condition. Further, 17% were receiving psychopharmacologlcal treatment, but not one PGD patient was in therapy.